Laura E. Bendzick

2.5k total citations
27 papers, 1.5k citations indexed

About

Laura E. Bendzick is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Laura E. Bendzick has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 14 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Laura E. Bendzick's work include Immune Cell Function and Interaction (24 papers), CAR-T cell therapy research (11 papers) and T-cell and B-cell Immunology (9 papers). Laura E. Bendzick is often cited by papers focused on Immune Cell Function and Interaction (24 papers), CAR-T cell therapy research (11 papers) and T-cell and B-cell Immunology (9 papers). Laura E. Bendzick collaborates with scholars based in United States, Canada and United Kingdom. Laura E. Bendzick's co-authors include Dan S. Kaufman, Melissa A. Geller, Jeffrey S. Miller, David Hermanson, Martin Felices, David A. Knorr, Zhenya Ni, Peter Hinderlie, Melinda K. Hexum and Laurence J.N. Cooper and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Laura E. Bendzick

25 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura E. Bendzick United States 15 1.1k 973 435 110 108 27 1.5k
Herschel Wallen United States 7 715 0.6× 713 0.7× 580 1.3× 107 1.0× 145 1.3× 7 1.4k
Jan Spanholtz Netherlands 23 1.2k 1.1× 922 0.9× 281 0.6× 317 2.9× 109 1.0× 40 1.5k
Wouter Scheper Netherlands 11 924 0.8× 773 0.8× 310 0.7× 98 0.9× 69 0.6× 15 1.3k
Melissa M. Berrien-Elliott United States 19 1.5k 1.3× 1.0k 1.0× 339 0.8× 253 2.3× 73 0.7× 49 1.9k
Nan Ring United States 7 782 0.7× 464 0.5× 258 0.6× 58 0.5× 58 0.5× 12 1.1k
Mark J. Cantwell United States 10 697 0.6× 425 0.4× 397 0.9× 71 0.6× 137 1.3× 23 1.2k
Srinivas S. Somanchi United States 15 1.1k 1.0× 880 0.9× 224 0.5× 195 1.8× 102 0.9× 30 1.3k
Agnès Moreau‐Aubry France 17 806 0.7× 433 0.4× 448 1.0× 108 1.0× 66 0.6× 30 1.3k
Matthias Leisegang Germany 20 711 0.6× 838 0.9× 283 0.7× 43 0.4× 249 2.3× 35 1.0k
Ling Yi United States 9 479 0.4× 616 0.6× 331 0.8× 143 1.3× 76 0.7× 16 922

Countries citing papers authored by Laura E. Bendzick

Since Specialization
Citations

This map shows the geographic impact of Laura E. Bendzick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura E. Bendzick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura E. Bendzick more than expected).

Fields of papers citing papers by Laura E. Bendzick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura E. Bendzick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura E. Bendzick. The network helps show where Laura E. Bendzick may publish in the future.

Co-authorship network of co-authors of Laura E. Bendzick

This figure shows the co-authorship network connecting the top 25 collaborators of Laura E. Bendzick. A scholar is included among the top collaborators of Laura E. Bendzick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura E. Bendzick. Laura E. Bendzick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chacón, Jeremy M., Laura E. Bendzick, Mihir Shetty, et al.. (2025). Chronic NK cell activation results in a dysfunctional, tissue resident–like state mediated by KLF2 deficiency. Blood. 146(25). 3059–3071.
2.
Kumar, Akhilesh, Alexander J. Lenvik, Martin Felices, et al.. (2025). The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity. The Journal of Immunology. 214(11). 2961–2975.
3.
Zorko, Nicholas A., Peter Hinderlie, Amanda J. Russell, et al.. (2024). Effect of camelid B7-H3 tri-specific killer engagers on natural killer cells in patients with prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 155–155. 1 indexed citations
4.
Felices, Martin, Laura E. Bendzick, Behiye Kodal, et al.. (2023). Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. Cancer Immunology Research. 11(5). 674–686. 8 indexed citations
5.
Kennedy, Philippa R, Daniel A. Vallera, Behiye Kodal, et al.. (2023). A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Frontiers in Immunology. 14. 1060905–1060905. 14 indexed citations
6.
Schirm, Dawn K., et al.. (2022). Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight. 7(15). 30 indexed citations
7.
Kamiński, Michał F., Laura E. Bendzick, Behiye Kodal, et al.. (2022). TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity. Journal for ImmunoTherapy of Cancer. 10(9). e004725–e004725. 14 indexed citations
8.
Yang, Jianbo, Qianjin Liao, Matt A. Price, et al.. (2021). Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. Translational Oncology. 16. 101318–101318. 14 indexed citations
9.
Felices, Martin, Todd Lenvik, Behiye Kodal, et al.. (2020). Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. Cancer Immunology Research. 8(9). 1139–1149. 51 indexed citations
10.
Pomeroy, Emily J., John Hunzeker, Mitchell G. Kluesner, et al.. (2019). A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy. 28(1). 52–63. 139 indexed citations
11.
Felices, Martin, Laura E. Bendzick, Caitlin Ryan, et al.. (2019). Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. Gynecologic Oncology. 153(1). 149–157. 82 indexed citations
12.
Felices, Martin, Alexander J. Lenvik, Ron McElmurry, et al.. (2018). Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. 3(3). 184 indexed citations
13.
Felices, Martin, Behiye Kodal, Laura E. Bendzick, et al.. (2018). Cytokine-induced memory-like natural killer cells demonstrate enhanced effector functions against ovarian cancer. Gynecologic Oncology. 149. 51–51. 2 indexed citations
14.
Felices, Martin, Craig E. Eckfeldt, Todd Lenvik, et al.. (2017). Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models. Blood. 130. 4465–4465. 1 indexed citations
15.
Felices, Martin, Sami Chu, Behiye Kodal, et al.. (2017). IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecologic Oncology. 145(3). 453–461. 103 indexed citations
16.
Angelos, Mathew G., Beau R. Webber, Robert Blum, et al.. (2017). Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood. 129(26). 3428–3439. 53 indexed citations
17.
Hermanson, David, Laura E. Bendzick, & Dan S. Kaufman. (2016). Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer. Methods in molecular biology. 1441. 277–284. 8 indexed citations
18.
Geller, Melissa A., David A. Knorr, Laura E. Bendzick, et al.. (2013). Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy. 15(10). 1297–1306. 58 indexed citations
19.
Keane, Thomas, Laura E. Bendzick, Scott C. Kogan, et al.. (2012). A Dominantly Acting Murine Allele of Mcm4 Causes Chromosomal Abnormalities and Promotes Tumorigenesis. PLoS Genetics. 8(11). e1003034–e1003034. 32 indexed citations
20.
Collier, Lara S., David J. Adams, Christopher S. Hackett, et al.. (2009). Whole-Body Sleeping Beauty Mutagenesis Can Cause Penetrant Leukemia/Lymphoma and Rare High-Grade Glioma without Associated Embryonic Lethality. Cancer Research. 69(21). 8429–8437. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Herschel Wallen Breakdown of academic impact, for papers by Jan Spanholtz Breakdown of academic impact, for papers by Wouter Scheper Breakdown of academic impact, for papers by Melissa M. Berrien-Elliott Breakdown of academic impact, for papers by Nan Ring Breakdown of academic impact, for papers by Mark J. Cantwell Breakdown of academic impact, for papers by Srinivas S. Somanchi Breakdown of academic impact, for papers by Agnès Moreau‐Aubry Breakdown of academic impact, for papers by Matthias Leisegang Breakdown of academic impact, for papers by Ling Yi
Rankless by CCL
2026